Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

long-term. Median change from baseline viral load (HIV RNA) was -2.1, -2.2, -2.3, -2.3 (log10) at weeks 48, 96, 144 and 168, respectively. Mean change from baseline CD4 (cells/microliter) count was +121, +144, +158 and +143 at the same time points.

Key Safety Findings

Safety analyses were performed on data from all patients who received any vicriviroc treatment (N=205). AIDS-associated opportunistic infections and conditions were observed infrequently and sporadically. Infections involving the upper and lower respiratory tract were the only other infections or adverse events that occurred in 5 percent or more of patients. Elevations of liver enzymes and bilirubin were noted, but were not characteristic of drug-induced liver injury and were judged to be not related to vicriviroc. These infections and other adverse events observed in these patients were generally consistent with expectations for patients with advanced HIV infection and with the multiple drugs being administered.

Status of Vicriviroc Phase III Studies in Treatment-Experienced Patients

Schering-Plough has completed patient enrollment in two large Phase III clinical studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluating vicriviroc 30 mg once daily in combination with an optimized background antiretroviral regimen containing a ritonavir-boosted protease inhibitor compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are few exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies involve a total of more than 850 patients and are currently ongoing
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
(Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
(Date:7/9/2014)... the first time, researchers have access to detailed information ... health care. A new study, called Our Health Counts, ... challenges faced by urban Aboriginal people in Canada ... The findings, published today in BMJ Open , ... the general population. , Researchers interviewed 554 First Nations ...
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... policing injection drug users in Russia might contribute ... A study, conducted by researchers from Boston University ... with St. Petersburg Pavlov State University, sought to ... health outcomes of a cohort of HIV-positive people ... who were arrested by police were more likely ...
(Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
Breaking Medicine News(10 mins):Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... the illegal organ trade in Tamil Nadu, led to the ... illegal organ trade; their license has been revoked. This operation ... the sale of kidneys by poor fisherwomen on Chennai coast. ... cause notices. ,The laws pertaining to organ transplant ...
... developed a new method of delivering drugs to fight ... which they say would be less// physically traumatic to ... at the National University of Singapore's department of chemical ... they cannot be detected under a standard microscope, are ...
... Bird flu patients who get early treatment with the antiviral ... steroids can do more harm// than good, the World Health ... agency was reporting on the preliminary conclusions of international experts ... treatments, including the attempt by doctors in some countries to ...
... religious community have called upon the US Congress to cast ... , This program, State Children's Health Insurance ... children whose parents are not offered health insurance through their ... April 23, faith leaders, heads of the Detroit Medical Center's ...
... Pharmaceutical companies will be required to declare the production ... planning to introduce// into the Thai market, Siriwat Thiptaradol, ... the Bangkok Post reports. ,According to ... is included in a new bill being considered by ...
... more of a burden for the women than a boon. The ... //the right kind of health care that is needed. They are ... of having insurance. , A national survey conducted by the ... on health and social issues found that the women patients don’t ...
Cached Medicine News:Health News:Tamiflu Key to Treat Bird Flu, Avoid Steroids: WHO 2Health News:Call To Extend Health Insurance To All Children 2Health News:Thailand Directs Pharma Companies to Declare Production Cost of Drugs 2Health News:Costlier Health Care Weigh Downs the Women 2Health News:Costlier Health Care Weigh Downs the Women 3
... Mumps IgG Enzyme- linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to Mumps virus ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... Ultra Laboratory has been uniquely designed ... single facility to integrated networks spanning ... to management reporting and accounts receivable, ... precise laboratory management. All system modules ...
Medicine Products: